Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

In a turbulent market environment, SLRN stock has reached a 52-week low, trading at $1.85. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a definitive ...